LT4115879T - Farmacinė kompozicija, apimanti hmg-coa reduktazės inhibitorius ir fenofibratą - Google Patents

Farmacinė kompozicija, apimanti hmg-coa reduktazės inhibitorius ir fenofibratą

Info

Publication number
LT4115879T
LT4115879T LTEP22192821.1T LT22192821T LT4115879T LT 4115879 T LT4115879 T LT 4115879T LT 22192821 T LT22192821 T LT 22192821T LT 4115879 T LT4115879 T LT 4115879T
Authority
LT
Lithuania
Prior art keywords
fenofibrate
hmg
pharmaceutical composition
coa reductase
reductase inhibitors
Prior art date
Application number
LTEP22192821.1T
Other languages
English (en)
Inventor
Hitendra Netlal RAHANGDALE
Narendra Bhagwatbhai PRAJAPATI
Satyavan Shivajirao Dhavale
Venkataramana NAIDU
Original Assignee
Intas Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72266598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4115879(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intas Pharmaceuticals Ltd. filed Critical Intas Pharmaceuticals Ltd.
Publication of LT4115879T publication Critical patent/LT4115879T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP22192821.1T 2019-07-31 2020-07-30 Farmacinė kompozicija, apimanti hmg-coa reduktazės inhibitorius ir fenofibratą LT4115879T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921030870 2019-07-31
EP19201186 2019-10-02

Publications (1)

Publication Number Publication Date
LT4115879T true LT4115879T (lt) 2026-01-26

Family

ID=72266598

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP22192821.1T LT4115879T (lt) 2019-07-31 2020-07-30 Farmacinė kompozicija, apimanti hmg-coa reduktazės inhibitorius ir fenofibratą

Country Status (20)

Country Link
US (1) US20220273652A1 (lt)
EP (3) EP4115879B1 (lt)
JP (1) JP7692889B2 (lt)
CN (1) CN114173786A (lt)
AU (1) AU2020320448B2 (lt)
BR (1) BR112022001514A2 (lt)
CA (1) CA3148035A1 (lt)
CL (1) CL2022000198A1 (lt)
CO (1) CO2022000808A2 (lt)
DK (1) DK4115879T3 (lt)
ES (1) ES2931301T3 (lt)
HR (1) HRP20251674T1 (lt)
LT (1) LT4115879T (lt)
MX (1) MX2022001178A (lt)
MY (1) MY206722A (lt)
PH (1) PH12021553276A1 (lt)
PL (1) PL3833335T3 (lt)
RS (1) RS63740B1 (lt)
SI (1) SI4115879T1 (lt)
WO (1) WO2021019493A1 (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114903862B (zh) * 2022-06-15 2023-08-22 湖北中古生物制药有限公司 一种多廿烷醇阿托伐他汀钙复方制剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1415295A (en) 1971-10-14 1975-11-26 Orchimed Sa Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20050096391A1 (en) 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
CA2540984C (en) 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
MXPA06003813A (es) 2003-10-10 2006-06-14 Lifecycle Pharma As Forma solida de dosificacion que comprende un fibrato y una estatina.
CN1960712B (zh) * 2004-05-21 2011-04-20 阿库-伯雷克技术公司 包含多个片段的刻痕药片
RU2007133601A (ru) * 2005-02-10 2009-03-20 Лайфсайкл Фарма А/С (Dk) УСТОЙЧИВАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ФИКСИРОВАННУЮ ДОЗУ КОМБИНАЦИИ ФЕНОФИБРАТА И ИНГИБИТОРА HMG-CoA-РЕДУКТАЗЫ
BRPI0520821A2 (pt) * 2005-12-28 2009-06-30 Teva Pharma formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
US20080096900A1 (en) * 2006-06-26 2008-04-24 Amgen Inc. Methods for treating atherosclerosis
WO2008075320A2 (en) * 2006-12-21 2008-06-26 Ranbaxy Laboratories Limited Antilipidemic pharmaceutical compositions and process for preparation thereof
AU2008358622A1 (en) 2008-06-27 2009-12-30 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of rosuvastatin calcium
JP2012096998A (ja) 2009-02-27 2012-05-24 Kowa Co 安定なカプセル製剤及びその製造方法
US20110311625A1 (en) 2010-06-14 2011-12-22 Amruth Gowda Doddaveerappa Solid dosage forms of fenofibrate
CN103356500A (zh) * 2012-03-30 2013-10-23 肖广常 一种瑞舒伐他汀钙非诺贝特酸胆碱盐择时渗透泵控释片及其制备方法
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
TWI605759B (zh) 2013-03-29 2017-11-21 大阪曹達股份有限公司 調製二氧化氯溶液用的錠劑
KR102240429B1 (ko) * 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형

Also Published As

Publication number Publication date
PL3833335T3 (pl) 2023-01-02
AU2020320448B2 (en) 2025-05-15
EP3833335A1 (en) 2021-06-16
ES2931301T3 (es) 2022-12-28
JP7692889B2 (ja) 2025-06-16
BR112022001514A2 (pt) 2022-03-22
EP4678233A3 (en) 2026-04-29
SI4115879T1 (sl) 2026-02-27
HRP20251674T1 (hr) 2026-02-13
PH12021553276A1 (en) 2022-09-12
DK4115879T3 (da) 2025-12-22
EP3833335B1 (en) 2022-08-31
CL2022000198A1 (es) 2022-09-23
CO2022000808A2 (es) 2022-02-07
EP4678233A2 (en) 2026-01-14
US20220273652A1 (en) 2022-09-01
CN114173786A (zh) 2022-03-11
JP2022542004A (ja) 2022-09-29
NZ785375A (en) 2025-07-25
WO2021019493A1 (en) 2021-02-04
AU2020320448A1 (en) 2022-02-17
MX2022001178A (es) 2022-02-22
RS63740B1 (sr) 2022-12-30
EP4115879B1 (en) 2025-12-03
CA3148035A1 (en) 2021-02-04
MY206722A (en) 2025-01-03
EP4115879A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
EP3891149A4 (en) RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP3891148A4 (en) RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
LT3946464T (lt) Junginiai ir jų konjugatai
EP3741374A4 (en) MTOR-INHIBITOR, PHARMACEUTICAL COMPOSITION AND ITS USES
LT3687506T (lt) Pakeistieji benzofuranas, benzopirolas, benzotiofenas ir struktūriškai susiję komplemento inhibitoriai
EP3805264A4 (en) ANTI-INTERLEUKIN 17A ANTIBODIES, PHARMACEUTICAL COMPOSITION AND USE
EP3293177A4 (en) Tyrosine kinase inhibitor and pharmaceutical composition comprising same
EP3278803A4 (en) Solid pharmaceutical dosage form of parp inhibitor, and application of solid pharmaceutical dosage form of parp inhibitor
EP3706741A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP3770148C0 (en) RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING IT AND ITS USE
IL287628A (en) Injectable pharmaceutical compositions and uses thereof
EP3849992A4 (en) Cd73 inhibitors and pharmaceutical uses thereof
EA201790590A1 (ru) Гуманизированное моноклональное антитело, ингибирующее ферментативную активность сосудисто-эндотелиальной липазы
EP3630113A4 (en) PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR
CL2015003561A1 (es) Composición farmacéutica para administración por vía oral para su uso para la prevención y/o el tratamiento de una enfermedad cardiovascular.
MX376135B (es) Composicion farmaceutica y combinacion terapeutica que comprende un inhibidor de la proteina de transferencia de colesteril ester e inhibidores de hmg coa reductasa
LT4115879T (lt) Farmacinė kompozicija, apimanti hmg-coa reduktazės inhibitorius ir fenofibratą
NO20101142A1 (no) Kombinasjonspreparat til behandling av hyperlipidemi og hyperkolesterolemi.
EP3939998A4 (en) PHARMACEUTICAL COMPOSITION WITH CD40 ANTIBODY AND USE THEREOF
IL291895A (en) mcl1 inhibitors and their uses
PT3833335T (pt) Composição farmacêutica compreendendo inibidores de hmg-coa redutase e fenofibrato
MA42696A (fr) COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR DE LA HMG-CoA REDUCTASE ET UN INHIBITEUR ECA
IL290031A (en) Aminothiolester compounds and uses thereof
EP4032535A4 (en) PHARMACEUTICAL COMPOSITION